Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Free Cash Flow (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Free Cash Flow for 15 consecutive years, with -$1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 24.65% to -$1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$5.5 million, a 15.68% increase, with the full-year FY2024 number at -$5.2 million, down 21.24% from a year prior.
  • Free Cash Flow was -$1.8 million for Q3 2025 at NovaBay Pharmaceuticals, up from -$3.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $634000.0 in Q4 2024 to a low of -$4.3 million in Q4 2021.
  • A 5-year average of -$1.7 million and a median of -$1.7 million in 2022 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 187.45% in 2024; the steepest drop was 277.43% in 2024.
  • NovaBay Pharmaceuticals' Free Cash Flow stood at -$4.3 million in 2021, then skyrocketed by 72.05% to -$1.2 million in 2022, then surged by 40.03% to -$725000.0 in 2023, then skyrocketed by 187.45% to $634000.0 in 2024, then plummeted by 390.22% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Free Cash Flow are -$1.8 million (Q3 2025), -$3.0 million (Q2 2025), and -$1.3 million (Q1 2025).